Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Friedrich

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Alimentary Pharmacology & Therapeutics|August 12, 2023
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel diseaseSimon Woelfel, Joel Dütschler, Marius König, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Nature Medicine|June 7, 2017
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Molecular Cancer Therapeutics|June 11, 2020
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid LeukemiaBettina Brauchle, Rebecca L Goldstein, Christine M Karbowski, et al.
Vaccines|November 26, 2024
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver DiseaseSimon Woelfel, Daniel Junker, Irina Bergamin, et al.
JACC. Cardiovascular Imaging|December 6, 2025
Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA TrialRaymond Y Kwong, Bobby Heydari, Siddique Abbasi, et al.
Nature Medicine|October 22, 2021
IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapiesMatthias Friedrich, Mathilde Pohin, Matthew A Jackson, et al.
Annals of the Rheumatic Diseases|May 24, 2025
CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissueFeng Liu, Hui Shi, Jason D Turner, et al.
Med (New York, N.Y.)|June 1, 2022
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseasesIlya Korsunsky, Kevin Wei, Mathilde Pohin, et al.
Nature Immunology|October 22, 2024
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseTom Thomas, Matthias Friedrich, Charlotte Rich-Griffin, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Alimentary Pharmacology & Therapeutics|August 12, 2023
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel diseaseSimon Woelfel, Joel Dütschler, Marius König, et al.
Nature Medicine|April 4, 2017
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Nature Medicine|June 7, 2017
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel diseaseNathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, et al.
Molecular Cancer Therapeutics|June 11, 2020
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid LeukemiaBettina Brauchle, Rebecca L Goldstein, Christine M Karbowski, et al.
Vaccines|November 26, 2024
STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver DiseaseSimon Woelfel, Daniel Junker, Irina Bergamin, et al.
JACC. Cardiovascular Imaging|December 6, 2025
Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA TrialRaymond Y Kwong, Bobby Heydari, Siddique Abbasi, et al.
Nature Medicine|October 22, 2021
IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapiesMatthias Friedrich, Mathilde Pohin, Matthew A Jackson, et al.
Annals of the Rheumatic Diseases|May 24, 2025
CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissueFeng Liu, Hui Shi, Jason D Turner, et al.
Med (New York, N.Y.)|June 1, 2022
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseasesIlya Korsunsky, Kevin Wei, Mathilde Pohin, et al.
Nature Immunology|October 22, 2024
A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseTom Thomas, Matthias Friedrich, Charlotte Rich-Griffin, et al.
Pageof 9